Results 111 to 120 of about 19,727 (209)

Recent advances in managing chronic HCV infection: Focus on therapy in patients with severe liver disease [PDF]

, 2016
Chronic hepatitis C virus (HCV) infection still represents a major public health problem, as it is thought to be responsible for more than 350,000 deaths around the globe on a yearly basis.
Maan, R. (Raoel), Meer, A.J.P. (Adriaan) van der   +1 more
core   +5 more sources

Pediatric liver diseases: current challenges and future perspectives [PDF]

, 2015
Chronic liver diseases in children represent a rising problem with significant effects on public health. In fact, several pediatric liver diseases are precursors of adult chronic hepatopathies, cirrhosis and hepatocellular carcinoma.
Alisi, Anna, Alterio, Arianna, Della Corte, Claudia, Mosca, Antonella, Nobili, Valerio, Vania, Andrea   +5 more
core   +1 more source

Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis [PDF]

, 2020
Barclay, Stephen T., Boyle, Alison, Datta, Shouren, Heydtmann, Mathis, Marra, Fiona, Peters, Erica, Priest, Matthew, Ritchie, Trina   +7 more
core   +3 more sources

Impact of a treatment as prevention strategy on hepatitis C virus transmission and on morbidity in people who inject drugs [PDF]

, 2015
Background: Highly effective direct-acting antiviral (DAA) regimens (90% efficacy) are becoming available for hepatitis C virus (HCV) treatment. This therapeutic revolution leads us to consider possibility of eradicating the virus.
Cousien, Anthony, Deuffic-Burban, Sylvie, Dhersin, Jean-Stéphane, Jauffret-Roustide, Marie, Tran, Viet Chi, Yazdanpanah, Yazdan   +5 more
core   +3 more sources

Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

Infection and Drug Resistance, 2018
Ossama A Ahmed,1 Hany H Kaisar,1 Rehab Badawi,2 Nehad Hawash,2 Hossam Samir,1 Sherif ST Shabana,1 Mohamed Hassan A Fouad,1 Fatma H Rizk,3 Samy A Khodeir,4 Sherief Abd-Elsalam2 1Department of Internal Medicine, Faculty of Medicine, Ain Shams University ...
Ahmed OA, Kaisar HH, Badawi R, Hawash N, Samir H, Shabana SST, Fouad MHA, Rizk FH, Khodeir SA, Abd-Elsalam S   +9 more
doaj  

Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials

Therapeutics and Clinical Risk Management, 2017
Young-Mo Yang, Eun Joo Choi Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, South Korea Background: With the appearance of oral direct-acting antivirals (DAAs), the field of hepatitis C virus (HCV) treatment has been ...
Yang YM, Choi EJ
doaj  

Avances en hepatitis C

Revista del Hospital Italiano de Buenos Aires
La hepatitis C es la principal causa de hepatitis crónica, cirrosis y cáncer de hígado, así como la indicación más común de trasplante hepático en la Argentina y muchos otros países.
Ezequiel Mauro, Sebastián Marciano, Omar Galdame, Adrián Gadano   +3 more
doaj  

Short-Term Clinical and Immunologic Outcomes Conditional on SVR12 in Hepatitis C Virus-Associated Cryoglobulinemic Vasculitis Treated With Direct-Acting Antivirals: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Boonpheng B, Ungprasert P.
europepmc   +1 more source

Potential Drug Interactions in Psychiatric Patients Undergoing Pangenotypic Therapy for Hepatitis C Virus Infection. [PDF]

Pharmaceuticals (Basel)
Dybowska D, Pawłowska M, Kozielewicz D.
europepmc   +1 more source

Histopathological features and eight-week split-tablet sofosbuvir/velpatasvir treatment in young children with acute hepatitis C: a case-series study. [PDF]

BMC Infect Dis
Pan YJ, Chen RY, Ai YQ, Zeng QL.
europepmc   +1 more source